Genetic variation that is present in the serotonin transporter gene (SLC6A4) has recently been studied in the light of treatment options for nervous disorders concerning mental health such as anxiety and depression.

Genetic variation of the SLC6A4 is reported to be affecting the anxiety and depression disorders and such that the impact of the effect of medicinal drugs for these disorders have been affected. The anxiety tests run for this purpose were given the name of trait anxiety, which is a defined characteristic of an individual’s personality. The trait anxiety is then linked to the genetic variations in the SLC6A4 and that triggers their feeling of threat a distinguishes what they are anxious about and whatnot. According to recent studies, the sequence of polymorphisms in the SLC6A4 was associated with personalized gene differences of people. These differences include anxiety traits, the gene expression of an individual and the body’s response to antidepressant formulas.

Studies conducted in the light of this topic yielded the result that genetic variations in SLC6A4 impacted the amount of serotonin receptors in the brain. The serotonin receptors in the brain are responsible for the uptake of any neurotransmitter. So, when the common antidepressant (selective serotonin reuptake inhibitor (SSRI)) used for the treatment of anxiety and depression in humans was tested on animals, the animals faced the anxiogenic effect. Basically, the SLC6A4 is present in the insula cortex which is that part of the brain that receives information about sensations coming from the body. This information is then integrated with cognitive information in our brain to feel different moods, thoughts, and feelings.

Humans face the anxiogenic effect in the early stages of their treatment, which makes it clear why SLC6A4 could be the reason why some people do not respond well to anti-depressants and rather need personalized therapy for their disorders. Every person faces different chemical reactions because of their genetic variations, which is why a personalized therapy approach is needed to deal with anxiety and depression disorders.

When you study about genetic variations inSLC6A4, you will become aware of the mechanisms that different people experience in different ways. People have anxiety and depression disorders about different things, which is why, along with pharmaceutical drugs, cognitive behavioral therapies are needed to retrain and redirect the though patterns of the affected individuals.

According to the results of multiple studies, the SLC6A4 repeat region can be a cause of triggering the anxiety trait. This happens mainly due to the neurochemical changes in brain areas which further affect the processing of information about feelings and thoughts. This is the main reason why people affected by anxiety and depression may not understand your concerns and reassurance easily. A lot of patients face resistance to SLC6A4 which brings forward the need to create personalized therapy treatments for patients according to their concerns and difficulties that they face. Through this, anxiety and depression disorders can be solved more effectively.